Dexamethasone prophylaxis for paclitaxel hypersensitivity

Journal of Oncology Pharmacy Practice

Volumn 8, Issue 2-3, 2002, Pages 81-87

  Gilbar, Peter ^a   Ridge, Alison ^a  

^a Toowoomba Health Services   (Australia)

Author keywords

Dexamethasone; Hypersensitivity reactions; Paclitaxel; Premedication; Prophylaxis

Indexed keywords

CARBOPLATIN; CHLORPHENIRAMINE; CIMETIDINE; CISPLATIN; CLEMASTINE; CONTRAST MEDIUM; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; EPIRUBICIN; FAMOTIDINE; GEMCITABINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; IFOSFAMIDE; LORATADINE; METHYLPREDNISOLONE; ORPHENADRINE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; PROMETHAZINE; RANITIDINE; SEROTONIN 3 ANTAGONIST; TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; EMOTIONAL DISORDER; FEMALE; HEAD AND NECK CANCER; HUMAN; INCIDENCE; INSOMNIA; LUNG NON SMALL CELL CANCER; MALE; MEDICAL LITERATURE; MEDICAL RECORD; MEMORY DISORDER; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; OVARY CANCER; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER;

EID: 0036992821     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155202jp096oa     Document Type: Article

References (32)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
2. Kohler DR, Goldspiel BR. Paclitaxel (Taxol). Pharmacotherapy 1994; 14: 3-34.
3. Kris MG, O'Connell JP, Gralla RJ, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605-607.
4. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-93.
5. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24: 767-79.
6. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-68.
7. Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of β-adrenergic antagonists. Arch Intern Med 1985; 145: 2197-200.
8. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-105.
9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
10. Uziely B, Jeffers S, Muggia F. Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. (letter). Ann Oncol 1994; 5: 474.
11. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997; 8: 611-14.
12. Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 1998; 69: 122-24.
13. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999; 125: 427-29.
14. Gennari A, Salvadori B, Tognoni A, Conte PF. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 1996; 7: 978-79.
15. Parikh B, Khanolkar S, Advani SH, Dhabhar B, Chandra M. Safety profile of single-dose dexamethasone premedication for paclitaxel. J Clin Oncol 1996; 14: 2189-90.
16. Boehm DK, Maksymiuk AW. Paclitaxel premedication regimens. J Natl Cancer Inst 1996; 88: 463-65.
17. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-70.
18. Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995; 22 (Suppl 12): 41-45.
19. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 1325-30.
20. Fleming GF, Kugler JW, Hoffman PC, et al. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol 1998; 16: 2032-37.
21. Conte PF, Gennari A, Donati S, et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 2001; 68: 171-79.
22. Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12: 1133-37.
23. Zanetta G, Fei F, Parma G, et al. Paclitaxel, ifosmide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999; 10: 1171-74.
24. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Disp 1995; 23: 506-12.
25. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002; 84: 420-25.
26. Markman M, Kennedy A, Webster K, et al. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. (letter). J Clin Oncol 1997; 15: 3517.
27. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-59.
28. Haynes RC. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In Gilman AG, Rall TW, Nies AS, Taylor P eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 8th ed. New York: Macmillan Publishing Co., 1990: 1431-62.
29. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987; 317: 845-49.
30. Ellul-Micallef R, Fenech FF. Intravenous prednisolone in chronic bronchial asthma. Thorax 1975; 30: 312.
31. Kris MG, Baltzer L, Pisters KMW, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer 1993; 72: 3436-42.
32. Siderov J, Wendel N, Davis ID. Non-sedating antihistamines for premedication in ambulatory oncology patients. J Pharm Pract Res 2002; 32: 108-109.